Trade Regeneron Pharmaceuticals, Inc. (Extended hours) - REGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.96 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02354% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001318% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 629.95 |
| Open | 635.29 |
| 1-Year Change | -33.99% |
| Day's Range | 621.4 - 639.5 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 28, 2025 | 629.95 | -8.32 | -1.30% | 638.27 | 642.38 | 626.95 |
| Mar 27, 2025 | 629.95 | -4.01 | -0.63% | 633.96 | 642.95 | 629.50 |
| Mar 26, 2025 | 629.95 | -5.00 | -0.79% | 634.95 | 642.94 | 628.70 |
| Mar 25, 2025 | 634.47 | -26.48 | -4.01% | 660.95 | 665.74 | 631.27 |
| Mar 24, 2025 | 654.96 | 1.01 | 0.15% | 653.95 | 666.53 | 653.95 |
| Mar 21, 2025 | 658.32 | -1.63 | -0.25% | 659.95 | 665.34 | 650.95 |
| Mar 20, 2025 | 662.95 | -13.35 | -1.97% | 676.30 | 676.30 | 659.95 |
| Mar 19, 2025 | 662.95 | 7.99 | 1.22% | 654.96 | 674.49 | 654.96 |
| Mar 18, 2025 | 663.95 | -15.50 | -2.28% | 679.45 | 679.45 | 663.80 |
| Mar 17, 2025 | 676.95 | 20.00 | 3.04% | 656.95 | 679.60 | 656.95 |
| Mar 14, 2025 | 662.45 | -24.00 | -3.50% | 686.45 | 686.45 | 656.95 |
| Mar 13, 2025 | 680.56 | 0.60 | 0.09% | 679.96 | 697.85 | 677.28 |
| Mar 12, 2025 | 688.53 | -34.42 | -4.76% | 722.95 | 722.95 | 684.18 |
| Mar 11, 2025 | 717.95 | -28.26 | -3.79% | 746.21 | 749.95 | 712.32 |
| Mar 10, 2025 | 745.14 | 35.50 | 5.00% | 709.64 | 747.92 | 702.95 |
| Mar 7, 2025 | 706.95 | 10.50 | 1.51% | 696.45 | 728.87 | 690.15 |
| Mar 6, 2025 | 696.45 | 13.49 | 1.98% | 682.96 | 700.61 | 682.12 |
| Mar 5, 2025 | 685.96 | 11.01 | 1.63% | 674.95 | 692.46 | 672.67 |
| Mar 4, 2025 | 674.95 | -10.11 | -1.48% | 685.06 | 697.23 | 669.95 |
| Mar 3, 2025 | 684.85 | -11.07 | -1.59% | 695.92 | 706.74 | 683.13 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Regeneron Company profile
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.| Industry: | Bio Therapeutic Drugs |
777 Old Saw Mill River Road
TARRYTOWN
NEW YORK 10591
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com